Cargando…

Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit

BACKGROUND: To report survival, spontaneous prognostic factors, and treatment efficacy in a French monocentric cohort of diffuse low-grade glioma (DLGG) patients over 35 years of follow-up. METHODS: A monocentric retrospective study of 339 patients diagnosed with a new DLGG between 01/01/1982 and 01...

Descripción completa

Detalles Bibliográficos
Autores principales: Obara, Tiphaine, Blonski, Marie, Brzenczek, Cyril, Mézières, Sophie, Gaudeau, Yann, Pouget, Celso, Gauchotte, Guillaume, Verger, Antoine, Vogin, Guillaume, Moureaux, Jean-Marie, Duffau, Hugues, Rech, Fabien, Taillandier, Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656991/
https://www.ncbi.nlm.nih.gov/pubmed/33194684
http://dx.doi.org/10.3389/fonc.2020.574679
_version_ 1783608442466861056
author Obara, Tiphaine
Blonski, Marie
Brzenczek, Cyril
Mézières, Sophie
Gaudeau, Yann
Pouget, Celso
Gauchotte, Guillaume
Verger, Antoine
Vogin, Guillaume
Moureaux, Jean-Marie
Duffau, Hugues
Rech, Fabien
Taillandier, Luc
author_facet Obara, Tiphaine
Blonski, Marie
Brzenczek, Cyril
Mézières, Sophie
Gaudeau, Yann
Pouget, Celso
Gauchotte, Guillaume
Verger, Antoine
Vogin, Guillaume
Moureaux, Jean-Marie
Duffau, Hugues
Rech, Fabien
Taillandier, Luc
author_sort Obara, Tiphaine
collection PubMed
description BACKGROUND: To report survival, spontaneous prognostic factors, and treatment efficacy in a French monocentric cohort of diffuse low-grade glioma (DLGG) patients over 35 years of follow-up. METHODS: A monocentric retrospective study of 339 patients diagnosed with a new DLGG between 01/01/1982 and 01/01/2017 was created. Inclusion criteria were patient age ≥18 years at diagnosis and histological diagnosis of WHO grade II glioma (according to 1993, 2007, and 2016 WHO classifications). The survival parameters were estimated using the Kaplan-Meier method with a 95% confidence interval. Differences in survival were tested for statistical significance by the log-rank test. Factors were considered significant when p ≤ 0.1 and p ≤ 0.05 in the univariate and multivariate analyses, respectively. RESULTS: A total of 339 patients were included with a median follow-up of 8.7 years. The Kaplan-Meier median overall survival was 15.7 years. At the time of radiological diagnosis, Karnofsky Performance Status score and initial tumor volume were significant independent prognostic factors. Oncological prognostic factors were the extent of resection for patients who underwent surgery and the timing of radiotherapy for those concerned. In this study, patients who had delayed radiotherapy (provided remaining low grade) did not have worse survival compared with patients who had early radiotherapy. The functional capabilities of the patients were preserved enough so that they could remain independent during at least three quarters of the follow-up. CONCLUSION: This large monocentric series spread over a long time clarifies the effects of different therapeutic strategies and their combination in the management of DLGG.
format Online
Article
Text
id pubmed-7656991
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76569912020-11-13 Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit Obara, Tiphaine Blonski, Marie Brzenczek, Cyril Mézières, Sophie Gaudeau, Yann Pouget, Celso Gauchotte, Guillaume Verger, Antoine Vogin, Guillaume Moureaux, Jean-Marie Duffau, Hugues Rech, Fabien Taillandier, Luc Front Oncol Oncology BACKGROUND: To report survival, spontaneous prognostic factors, and treatment efficacy in a French monocentric cohort of diffuse low-grade glioma (DLGG) patients over 35 years of follow-up. METHODS: A monocentric retrospective study of 339 patients diagnosed with a new DLGG between 01/01/1982 and 01/01/2017 was created. Inclusion criteria were patient age ≥18 years at diagnosis and histological diagnosis of WHO grade II glioma (according to 1993, 2007, and 2016 WHO classifications). The survival parameters were estimated using the Kaplan-Meier method with a 95% confidence interval. Differences in survival were tested for statistical significance by the log-rank test. Factors were considered significant when p ≤ 0.1 and p ≤ 0.05 in the univariate and multivariate analyses, respectively. RESULTS: A total of 339 patients were included with a median follow-up of 8.7 years. The Kaplan-Meier median overall survival was 15.7 years. At the time of radiological diagnosis, Karnofsky Performance Status score and initial tumor volume were significant independent prognostic factors. Oncological prognostic factors were the extent of resection for patients who underwent surgery and the timing of radiotherapy for those concerned. In this study, patients who had delayed radiotherapy (provided remaining low grade) did not have worse survival compared with patients who had early radiotherapy. The functional capabilities of the patients were preserved enough so that they could remain independent during at least three quarters of the follow-up. CONCLUSION: This large monocentric series spread over a long time clarifies the effects of different therapeutic strategies and their combination in the management of DLGG. Frontiers Media S.A. 2020-10-28 /pmc/articles/PMC7656991/ /pubmed/33194684 http://dx.doi.org/10.3389/fonc.2020.574679 Text en Copyright © 2020 Obara, Blonski, Brzenczek, Mézières, Gaudeau, Pouget, Gauchotte, Verger, Vogin, Moureaux, Duffau, Rech and Taillandier http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Obara, Tiphaine
Blonski, Marie
Brzenczek, Cyril
Mézières, Sophie
Gaudeau, Yann
Pouget, Celso
Gauchotte, Guillaume
Verger, Antoine
Vogin, Guillaume
Moureaux, Jean-Marie
Duffau, Hugues
Rech, Fabien
Taillandier, Luc
Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit
title Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit
title_full Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit
title_fullStr Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit
title_full_unstemmed Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit
title_short Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit
title_sort adult diffuse low-grade gliomas: 35-year experience at the nancy france neurooncology unit
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656991/
https://www.ncbi.nlm.nih.gov/pubmed/33194684
http://dx.doi.org/10.3389/fonc.2020.574679
work_keys_str_mv AT obaratiphaine adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit
AT blonskimarie adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit
AT brzenczekcyril adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit
AT mezieressophie adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit
AT gaudeauyann adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit
AT pougetcelso adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit
AT gauchotteguillaume adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit
AT vergerantoine adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit
AT voginguillaume adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit
AT moureauxjeanmarie adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit
AT duffauhugues adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit
AT rechfabien adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit
AT taillandierluc adultdiffuselowgradegliomas35yearexperienceatthenancyfranceneurooncologyunit